Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 August 20, 2026 Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections August 10, 2026 Harrow Announces Second Quarter 2026 Financial Results August 6, 2026 Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease July 27, 2026 Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 July 20, 2026 Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 July 20, 2026 Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting July 1, 2026 Harrow Announces Commercial Launch of BYOOVIZ® in the United States June 10, 2026 Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare